Opinion
Video
Future Directions for Type 2 Inflammation Management
Author(s):
Reynold A. Panettieri Jr., MD, examines the application of biologic therapies in the treatment of respiratory conditions.
- Biologics are currently available for asthma management and being studied in COPD patients. Where do you envision the potential place of biologic therapies in the treatment algorithm for patients with type 2 inflammation-driven COPD?
- How does the route of administration impact the treatment selection?
- What emerging therapies for type 2 inflammation related to respiratory diseases are you most excited about? What are clinical trial data showing in terms of exacerbation and hospitalization rates, patient quality of life, and general disease management?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Videos
Related Content
